These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21864618)

  • 1. Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
    Gabitzsch ES; Xu Y; Balint JP; Balcaitis S; Sanders-Beer B; Jones FR
    Vaccine; 2011 Oct; 29(45):8101-7. PubMed ID: 21864618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
    Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.
    Gabitzsch ES; Balint-Junior JP; Xu Y; Balcaitis S; Sanders-Beer B; Karl J; Weinhold KJ; Paessler S; Jones FR
    Vaccine; 2012 Nov; 30(50):7265-70. PubMed ID: 23041546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
    Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
    Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
    J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
    Gabitzsch ES; Xu Y; Balint JP; Hartman ZC; Lyerly HK; Jones FR
    Cancer Immunol Immunother; 2010 Jul; 59(7):1131-5. PubMed ID: 20361185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.
    Reynolds MR; Weiler AM; Piaskowski SM; Piatak M; Robertson HT; Allison DB; Bett AJ; Casimiro DR; Shiver JW; Wilson NA; Lifson JD; Koff WC; Watkins DI
    Vaccine; 2012 Jun; 30(30):4465-75. PubMed ID: 22569124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.
    Gabitzsch ES; Xu Y; Balcaitis S; Balint JP; Jones FR
    Cancer Gene Ther; 2011 May; 18(5):326-35. PubMed ID: 21233857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
    Morse MA; Chaudhry A; Gabitzsch ES; Hobeika AC; Osada T; Clay TM; Amalfitano A; Burnett BK; Devi GR; Hsu DS; Xu Y; Balcaitis S; Dua R; Nguyen S; Balint JP; Jones FR; Lyerly HK
    Cancer Immunol Immunother; 2013 Aug; 62(8):1293-301. PubMed ID: 23624851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.
    Quiroga D; Aldhamen YA; Godbehere S; Harding L; Amalfitano A
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28381403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
    Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
    Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.
    Sun C; Feng L; Zhang Y; Xiao L; Pan W; Li C; Zhang L; Chen L
    J Virol; 2012 Oct; 86(20):11031-42. PubMed ID: 22855499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
    Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
    J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
    Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
    J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
    Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
    Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.
    Almond N; Berry N; Stebbings R; Preston M; Ham C; Page M; Ferguson D; Rose N; Li B; Mee ET; Hassall M; Stahl-Hennig C; Athanasopoulos T; Papagatsias T; Herath S; Benlahrech A; Dickson G; Meiser A; Patterson S
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.